Molecular and functional neuroimaging of human opioid receptor pharmacology

Eugenii Rabiner; John D Beaver; Aidan Makwana; G Searle; C Long; P J Nathan; Rexford D Newbould; J Howard; Sam R Miller; M A Bush; S Hill; Richard R Reiley; Jan Passchier; R N Gunn; PM Matthews; E T Bullmore

doi:10.1038/mp.2011.83

Molecular and functional neuroimaging of human opioid receptor pharmacology

Eugenii Rabiner, John D Beaver, Aidan Makwana, G Searle, C Long, P J Nathan, Rexford D Newbould, J Howard, Sam R Miller, M A Bush, S Hill, Richard R Reiley, Jan Passchier, R N Gunn, PM Matthews, E T Bullmore

NIHR Maudsley Biomedical Research Centre (BRC)

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

The effects of GSK1521498, a new μ-opioid receptor antagonist, were imaged in the human brain using a combination of positron emission tomography and functional magnetic resonance imaging. (a) The occupancy of μ-opioid receptors by [11C]carfentanil, a radioligand for the opioid receptor, was measured with positron emission tomography at baseline and following the administration of GSK1521498 (50 mg). Compared with baseline, GSK1521498 significantly reduces radioligand binding, indicating that it has high affinity for the target in the human brain. (b) Brain activation by a palatable food stimulus was measured with functional magnetic resonance imaging after oral administration of GSK1521498 or naltrexone, another opioid antagonist. Yellow voxels show brain areas where GSK1521498 had significantly greater effects than naltrexone in attenuating reward-related activation; green voxels show areas where naltrexone had a greater effect than GSK1521498. z indicates the distance (mm), superior or inferior, to the intercommissural plane in standard stereotactic space. These results indicate that the pharmacodynamics of GSK1521498 can be measured, and differentiated from naltrexone, using functional magnetic resonance imaging. For more info on this topic, please refer to the article by Rabiner et al. on pages 826–835.

Original language	English
Article number	785
Journal	Molecular Psychiatry
Volume	16
Issue number	8
DOIs	https://doi.org/10.1038/mp.2011.83
Publication status	Published - 2011

Access to Document

10.1038/mp.2011.83

Cite this

Rabiner, E., Beaver, J. D., Makwana, A., Searle, G., Long, C., Nathan, P. J., Newbould, R. D., Howard, J., Miller, S. R., Bush, M. A., Hill, S., Reiley, R. R., Passchier, J., Gunn, R. N., Matthews, PM., & Bullmore, E. T. (2011). Molecular and functional neuroimaging of human opioid receptor pharmacology. Molecular Psychiatry, 16(8), Article 785. https://doi.org/10.1038/mp.2011.83

@article{39a3c8e6065741f89acc5f16962aeb8c,

title = "Molecular and functional neuroimaging of human opioid receptor pharmacology",

abstract = "The effects of GSK1521498, a new μ-opioid receptor antagonist, were imaged in the human brain using a combination of positron emission tomography and functional magnetic resonance imaging. (a) The occupancy of μ-opioid receptors by [11C]carfentanil, a radioligand for the opioid receptor, was measured with positron emission tomography at baseline and following the administration of GSK1521498 (50 mg). Compared with baseline, GSK1521498 significantly reduces radioligand binding, indicating that it has high affinity for the target in the human brain. (b) Brain activation by a palatable food stimulus was measured with functional magnetic resonance imaging after oral administration of GSK1521498 or naltrexone, another opioid antagonist. Yellow voxels show brain areas where GSK1521498 had significantly greater effects than naltrexone in attenuating reward-related activation; green voxels show areas where naltrexone had a greater effect than GSK1521498. z indicates the distance (mm), superior or inferior, to the intercommissural plane in standard stereotactic space. These results indicate that the pharmacodynamics of GSK1521498 can be measured, and differentiated from naltrexone, using functional magnetic resonance imaging. For more info on this topic, please refer to the article by Rabiner et al. on pages 826–835.",

author = "Eugenii Rabiner and Beaver, {John D} and Aidan Makwana and G Searle and C Long and Nathan, {P J} and Newbould, {Rexford D} and J Howard and Miller, {Sam R} and Bush, {M A} and S Hill and Reiley, {Richard R} and Jan Passchier and Gunn, {R N} and PM Matthews and Bullmore, {E T}",

year = "2011",

doi = "10.1038/mp.2011.83",

language = "English",

volume = "16",

journal = "Molecular Psychiatry",

issn = "1359-4184",

publisher = "Springer Nature [academic journals on nature.com]",

number = "8",

}

TY - JOUR

T1 - Molecular and functional neuroimaging of human opioid receptor pharmacology

AU - Rabiner, Eugenii

AU - Beaver, John D

AU - Makwana, Aidan

AU - Searle, G

AU - Long, C

AU - Nathan, P J

AU - Newbould, Rexford D

AU - Howard, J

AU - Miller, Sam R

AU - Bush, M A

AU - Hill, S

AU - Reiley, Richard R

AU - Passchier, Jan

AU - Gunn, R N

AU - Matthews, PM

AU - Bullmore, E T

PY - 2011

Y1 - 2011

N2 - The effects of GSK1521498, a new μ-opioid receptor antagonist, were imaged in the human brain using a combination of positron emission tomography and functional magnetic resonance imaging. (a) The occupancy of μ-opioid receptors by [11C]carfentanil, a radioligand for the opioid receptor, was measured with positron emission tomography at baseline and following the administration of GSK1521498 (50 mg). Compared with baseline, GSK1521498 significantly reduces radioligand binding, indicating that it has high affinity for the target in the human brain. (b) Brain activation by a palatable food stimulus was measured with functional magnetic resonance imaging after oral administration of GSK1521498 or naltrexone, another opioid antagonist. Yellow voxels show brain areas where GSK1521498 had significantly greater effects than naltrexone in attenuating reward-related activation; green voxels show areas where naltrexone had a greater effect than GSK1521498. z indicates the distance (mm), superior or inferior, to the intercommissural plane in standard stereotactic space. These results indicate that the pharmacodynamics of GSK1521498 can be measured, and differentiated from naltrexone, using functional magnetic resonance imaging. For more info on this topic, please refer to the article by Rabiner et al. on pages 826–835.

AB - The effects of GSK1521498, a new μ-opioid receptor antagonist, were imaged in the human brain using a combination of positron emission tomography and functional magnetic resonance imaging. (a) The occupancy of μ-opioid receptors by [11C]carfentanil, a radioligand for the opioid receptor, was measured with positron emission tomography at baseline and following the administration of GSK1521498 (50 mg). Compared with baseline, GSK1521498 significantly reduces radioligand binding, indicating that it has high affinity for the target in the human brain. (b) Brain activation by a palatable food stimulus was measured with functional magnetic resonance imaging after oral administration of GSK1521498 or naltrexone, another opioid antagonist. Yellow voxels show brain areas where GSK1521498 had significantly greater effects than naltrexone in attenuating reward-related activation; green voxels show areas where naltrexone had a greater effect than GSK1521498. z indicates the distance (mm), superior or inferior, to the intercommissural plane in standard stereotactic space. These results indicate that the pharmacodynamics of GSK1521498 can be measured, and differentiated from naltrexone, using functional magnetic resonance imaging. For more info on this topic, please refer to the article by Rabiner et al. on pages 826–835.

U2 - 10.1038/mp.2011.83

DO - 10.1038/mp.2011.83

M3 - Article

SN - 1359-4184

VL - 16

JO - Molecular Psychiatry

JF - Molecular Psychiatry

IS - 8

M1 - 785

ER -

Molecular and functional neuroimaging of human opioid receptor pharmacology

Abstract

Access to Document

Fingerprint

Cite this